title: [Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
abstract: The new direct oral anticoagulants directly targeting thrombin (factor IIa) or factor-Xa, are currently used for the treatment of deep venous thrombosis and pulmonary embolism (rivaroxaban, Xarelto) or for the prevention of systemic embolism in non-valvular atrial fibrillation (rivaroxaban; dabigatran, Pradaxa; Apixaban, Eliquis). Given their ease of use, it is expected that these drugs would be widely used in such long-term indications. Beyond their effectiveness, these treatments remain anticoagulant drugs, potentially responsible for bleeding complications, and specific measures should be defined in case of occurrence of such complications.
authors.forename: Gilles
authors.initials: G
authors.lastname: Pernod
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001780:Blood Coagulation Tests; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D006435:Renal Dialysis
chemical_list: D000925:Anticoagulants; D006490:Hemostatics